Alembic Pharmaceuticals Limited — Investor Meet, 12-05-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Alembic Pharmaceuticals reported Q4 revenue up 17% to Rs. 1,770 Cr, with EBITDA at Rs. 286 Cr (16% margin) and net profit at Rs. 157 Cr. FY25 revenue rose 7% to Rs. 6,672 Cr, net profit at Rs. 583 Cr. Growth was led by India (8%), US generics (20%), and ex-US markets (43%). R&D spend was Rs. 151 Cr (9% of sales), targeting peptides, injectables, and ophthalmics. Margins stable at ~70%, with improved facility utilization and R&D efficiency. FY26 outlook anticipates mid-teens growth in US generics, double-digit gains in ROW, API, and Indian businesses.